|GAP-134 Gap junction modifier|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||943134-39-2||SDF||Download SDF|
|Synonyms||Danegaptide;ZP1609;GAP134;GAP 134;ZP-1609;ZP 1609|
|Chemical Name||1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid|
|Solubility||DMSO||Storage||Store at -20°C|
|Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL). GAP-134 (Danegaptide), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. Gap junction modifier GAP-134, showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. GAP-134 is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, as already confirmed in phase I clinical trials.